

**AultCare Health Plans
Medical Oncology Code List**

*****Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact AultCare or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|--|--------------------------|---------|--------------------------|-------------------------|--------------------------|---------------------|---------------|
| 5-Fluorouracil- Injection | 5FU, Adrucil | J9190 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ado-Trastuzumab Emtansine | Kadcyla | J9354 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Aldesleukin | Proleukin, Interleukin-2 | J9015 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Amivantamab-vmjw | Rybrevant | J9061 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Aprepitant | Cinvanti | J0185 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Arsenic Trioxide | Trisenox | J9017 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Asparaginase | Erwinaze | J9019 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Asparaginase erwinia chrysanthemi (recombinant)-rywn | Rylaze | J9021 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Atezolizumab | Tecentriq | J9022 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Avelumab | Bavencio | J9023 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Azacitidine | Vidaza | J9025 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Azacitidine - oral | Onureg | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| BCG | TheraCys, Tice | J9030 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Belantamab Mafodotin-blmf | Blenrep | J9037 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Belinostat | Beleodaq | J9032 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL | Treanda | J9033 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL | Bendeka | J9034 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL | Belrapzo | J9036 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL (apotex) | | J9058 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|---------------------------------------|------------------|---------|--------------------------|----------------------|--------------------------|---------------------|---|
| Bendamustine HCL (baxter) | | J9059 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL (vivimusta) | | J9056 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab | Avastin | J9035 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab (Radiation Necrosis) | Avastin | J9035 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-adcd | Vegzelma | Q5129 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Vegzelma to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-adcd | Vegzelma | Q5129 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab-awwb | Mvasi | Q5107 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-awwb (Radiation Necrosis) | Mvasi | Q5107 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-bvzr | Zirabev | Q5118 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-bvzr | Zirabev | Q5118 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-maly | Alymsys | Q5126 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-maly (Radiation Necrosis) | Alymsys | Q5126 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Alymsys to treat Radiation Induced Necrosis of the CNS |
| Bleomycin | Blenoxane | J9040 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Blinatumomab | Blinicyto | J9039 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib | Velcade | J9041 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (fresenius kabi) | | J9048 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (hospira) | | J9049 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (maia) | | J9051 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Brentuximab Vedotin | Adcetris | J9042 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Burosumab-twza | Crysvita | J0584 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Cabazitaxel | Jevtana | J9043 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cabazitaxel (sandoz) | | J9064 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Calaspargase pegol-mknl | Asparlas | J9118 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Capecitabine - oral | Xeloda (150 mg) | J8520 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Capecitabine - oral | Xeloda (500 mg) | J8521 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Carboplatin | Paraplatin | J9045 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Carfilzomib | Kyprolis | J9047 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|---|-----------------------|---------|--------------------------|------------|--------------------------|---------------------|--|
| Carmustine | BICNU, BCNU | J9050 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Carmustine (accord) | | J9052 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cemiplimab-rlwc | Libtayo | J9119 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cetuximab | Erbitux | J9055 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Chlorambucil - oral | Leukeran | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Chlorambucil - oral | Leukeran | S0172 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Cisplatin | Platinol | J9060 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cladribine | Leustatin | J9065 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Clofarabine | Clolar | J9027 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cyclophosphamide - inj | Cytosan, Endoxan-Asta | J9070 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cyclophosphamide - inj (auromedic) | | J9071 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cyclophosphamide - inj (dr. reddy's) | | J9072 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cyclophosphamide - inj (ingenus) | | J9073 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacturer code: J9073 for Cyclophosphamide - inj, effective: 04/01/24 |
| Cyclophosphamide - inj (sandoz) | | J9074 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacturer code: J9074 for Cyclophosphamide - inj, effective: 04/01/24 |
| Cyclophosphamide Inj, not otherwise specified | | J9075 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New generic HCPC Code: J9075 for Cyclophosphamide inj, effective: 04/01/24 |
| Cytarabine | Ara-C | J9100 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cytarabine-Liposome | DepoCyt | J9098 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dacarbazine | DTIC-Dome | J9130 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dactinomycin | Cosmegen, Actinomycin | J9120 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Daratumumab | Darzalex | J9145 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Daratumumab and hyaluronidase-fihj | Darzalex Faspro | J9144 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Darbeoetin alfa | Aranesp | J0881 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Daunorubicin | Cerubidine | J9150 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Decitabine | Dacogen | J0894 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Decitabine (sun pharma) | | J0893 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Degarelix | Firmagon | J9155 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Denosumab | Xgeva, Prolia | J0897 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Denosumab | Xgeva, Prolia | J0897 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | Primary chemo pathway for the use of Xgeva to treat Giant Cell Tumor. |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|-----------------------------|--|---------|--------------------------|------------|--------------------------|---------------------|--|
| Denosumab-bbdz | Wyost, Jubbonti | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J3490 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J3590 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Dinutuximab | Unituxin | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dinutuximab | Unituxin | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Docetaxel | Taxotere | J9171 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Docetaxel (ingenus) | | J9172 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dostarlimab-gxly | Jemperli | J9272 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Doxorubicin HCL | Adriamycin | J9000 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Doxorubicin HCL (liposomal) | Doxil, Doxorubicin HCL (Liposomal) not otherwise specified | Q2050 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Durvalumab | Imfinzi | J9173 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J3490 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J3590 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Eflapegrastim-xnst | Rolvedon | J1449 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Elotuzumab | Empliciti | J9176 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Elranatamab-bcmm | Elrexio | J1323 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J1323 will replace NOC Code: C9165 & J9999 for Elrexio, effective: 04/01/24 |
| Elranatamab-bcmm | Elrexio | C9165 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Elranatamab-bcmm | Elrexio | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Enfortumab vedotin-efv | Padcev | J9177 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Epcoritamab-bysp | Epkinly | J9321 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Epirubicin | Ellence | J9178 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Epoetin alfa | Epogen, Procrit | J0885 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Epoetin alfa-epbx | Retacrit | Q5106 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|------------------------------------|-----------------------------|---------|--------------------------|-------------------------|--------------------------|---------------------|---|
| Eribulin mesylate | Halaven | J9179 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Etoposide - inj | Toposar, VePesid, Etopophos | J9181 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Etoposide - oral | Toposar | J8560 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Fam-trastuzumab deruxtecan-nxki | Enhertu | J9358 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Filgrastim | Neupogen | J1442 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Filgrastim-aafi | Nivestym | Q5110 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Filgrastim-ayow | Releuko | Q5125 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Filgrastim-sndz | Zarxio | Q5101 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Floxuridine | FUDR | J9200 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fludarabine Phosphate | Fludara, Oforta | J9185 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fosaprepitant | Emend | J1453 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fosaprepitant (focinvez) | | J1434 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | New manufacturer code: J1434 for Fosaprepitant, effective: 04/01/24 |
| Fosaprepitant (teva) | | J1456 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fosnetupitant/Palonosetron | Akynzeo | J1454 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fulvestrant | Faslodex | J9395 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fulvestrant (fresenius kabi) | | J9394 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fulvestrant (teva) | | J9393 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemcitabine | Gemzar | J9201 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemcitabine HCL in NaCL | Infugem | J9198 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemcitabine Hydrochloride (accord) | | J9196 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemtuzumab Ozogamicin | Mylotarg | J9203 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Glofitamab-gxbm | Columvi | J9286 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Goserelin acetate implant | Zoladex | J9202 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Granisetron - subcutaneous | Sustol | J1627 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Histrelin Implant | Vantas | J9225 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Idarubicin HCL - inj | Idamycin | J9211 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ifosfamide | Ifex, Mitoxana | J9208 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Inotuzumab Ozogamicin | Besponsa | J9229 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Interferon, alfa-2b, recombinant | Intron A | J9214 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|--|---|---------|--------------------------|------------|--------------------------|---------------------|--|
| Interferon, gamma-1b | Actimmune | J9216 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ipilimumab | Yervoy | J9228 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Irinotecan | Camptosar | J9206 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Irinotecan Liposome | Onivyde | J9205 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Isatuximab-irfc | Sarclisa | J9227 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ixabepilone | Ixempra | J9207 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lanreotide | Somatuline Depot | J1930 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lanreotide (cipla) | | J1932 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leucovorin - inj | Leucovorin Calcium | J0640 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (cipla) | | J1954 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J1950: 3.75mg) | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J1950 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J9217: 7.5mg) | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J9217 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J9218: 1mg) | Lupron | J9218 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Mesylate | Camcevi | J1952 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Levoleucovorin | Fusilev | J0641 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Levoleucovorin | Khapzory | J0642 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Liposome-encapsulated combination of Daunorubicin and Cytarabine | Vyxeos | J9153 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Loncastuximab tesirine-lpyl | Zynlonta | J9359 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lurbinectedin | Zepzelca | J9223 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Luspatercept-aamt | Reblozyl | J0896 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Margetuximab-cmkb | Margenza | J9353 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Melphalan (apotex) | | J9249 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacture code: J9249 for Melphalan, effective: 04/01/24 |
| Melphalan (hepzato) | | J9248 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacture code: J9248 for Melphalan, effective: 04/01/24 |
| Melphalan HCL - inj | Evomela | J9246 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Melphalan HCL - NOS inj | Alkeran | J9245 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Methotrexate (accord) | | J9255 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Methotrexate Sodium (J9250: 5mg) | Folex, Methotrexate | J9250 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Methotrexate Sodium, 50mg | | J9260 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|--|------------------|---------|--------------------------|-------------------------|--------------------------|---------------------|---------------|
| Mirvetuximab Soravtansine-gynx | Elahere | J9063 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mitomycin | Mutamycin | J9280 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mitomycin | Jelmyto | J9281 | Medical Oncology - CHEMO | Primary | PYELOCALYCEAL | Y | |
| Mitoxantrone HCL | Novantrone | J9293 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mogamulizumab-kpkc | Poteligeo | J9204 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mosunetuzumab-axgb | Lunsumio | J9350 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Moxetumomab pasudotox-tdfk | Lumoxiti | J9313 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Nadofaragen Firadenovec-vncg | Adstiladrin | J9029 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Naxitamab-gqgk | Danyelza | J9348 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Necitumumab | Portrazza | J9295 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Nelarabine | Arranon | J9261 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Nivolumab | Opdivo | J9299 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Nivolumab and Relatlimab-rmbw | Opdualag | J9298 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Obinutuzumab | Gazyva | J9301 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide depot | Sandostatin | J2353 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide depot | Sandostatin | J2353 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Octreotide non-depot | Sandostatin | J2354 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide non-depot | Sandostatin | J2354 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Ofatumumab | Arzerra | J9302 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Omacetaxine | Synribo | J9262 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Oxaliplatin | Eloxatin | J9263 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel | Nov-Onxol, Taxol | J9267 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel (albumin-bound) | Abraxane | J9264 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel albumin-bound (american regent) | | J9259 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel protein-bound (teva) | | J9258 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Palonosetron | Aloxi | J2469 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Panitumumab | Vectibix | J9303 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pegaspargase | Oncaspar | J9266 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pegfilgrastim, excludes biosimilar, 0.5 mg | Neulasta | J2506 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-apgf | Nyvepria | Q5122 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|---|--|---------|--------------------------|----------------------|--------------------------|---------------------|---------------|
| Pegfilgrastim-bmez | Ziextenzo | Q5120 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-cbqv | Udenyca | Q5111 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-fpgk | Stimufend | Q5127 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-jmdb | Fulphila | Q5108 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-pbbk | Fylnetra | Q5130 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Peginterferon, alfa-2a | Pegasys | S0145 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pembrolizumab | Keytruda | J9271 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed | Pemfexy | J9304 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed | Alimta, Pemetrexed not otherwise specified | J9305 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (accord) | | J9296 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (bluepoint) | | J9322 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (hospira) | | J9323 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (novaplus / hospira) | | J9294 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (pemrydi rtu) | | J9324 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (sandoz) | | J9297 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (teva) | | J9314 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pentostatin | Nipent | J9268 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pertuzumab | Perjeta | J9306 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pertuzumab / trastuzumab / hyaluronidase-zzxf | Phesgo | J9316 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Polatuzumab vedotin-piiq | Polivy | J9309 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Porfimer Sodium | Photofrin | J9600 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pralatrexate | Folotyn | J9307 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ramucirumab | Cyramza | J9308 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Retifanlimab-dlwr | Zynyz | J9345 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rituximab | Rituxan | J9312 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rituximab and Hyaluronidase Human | Rituxan Hycela | J9311 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rituximab-abbs | Truxima | Q5115 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Rituximab-arrx | Riabni | Q5123 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Rituximab-pvvr | Ruxience | Q5119 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Romidepsin (lyophilized) | Istodax | J9319 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Data Class: [Internal](#)

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|---|------------------|---------|--------------------------|------------|--------------------------|---------------------|--|
| Romidepsin (non-lyophilized) | | J9318 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ropeginterferon alfa-2b-njft | Besremi | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ropeginterferon alfa-2b-njft | Besremi | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sacituzumab govitecan-hziy | Trodelyv | J9317 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sargramostim | Leukine | J2820 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Siltuximab | Sylvant | J2860 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sipuleucel-T | Provenge | Q2043 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sirolimus protein-bound particles for injectable suspension (albumin bound) | Fyarro | J9331 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sodium Thiosulfate Injection | Pedmark | J0208 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Sodium Thiosulfate injection (hope) | | J0209 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New manufacturer code: J0209 for Sodium Thiosulfate effective: 04/01/24 |
| Streptozocin | Zanosar | J9320 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tafasitamab-cxix | Monjuvi | J9349 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tagraxofusp-erzs | Elzonris | J9269 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talimogene Laherparepvec | Imlygic | J9325 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talquetamab-tgvs | Talvey | J3055 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24 |
| Talquetamab-tgvs | Talvey | C9163 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talquetamab-tgvs | Talvey | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24 |
| Tbo-filgrastim | Granix | J1447 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Tebentafusp-tebn | Kimmtrak | J9274 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teclistamab-cqyv | Tecvayli | J9380 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Temozolomide - inj | Temodar | J9328 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Temozolomide - oral | Temodar | J8700 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Temsirolimus | Torisel | J9330 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teniposide | Vumon | Q2017 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Thiotepa | Thioplex | J9340 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tisotumab vedotin-tftv | Tivdak | J9273 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|------------------------------------|-------------------|---------|--------------------------|----------------------|--------------------------|---------------------|--|
| Tocilizumab | Actemra | J3262 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Actemra for CAR-T induced CRS |
| Tocilizumab | Actemra | J3262 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tocilizumab-bavi | Tofidence | Q5133 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | Q5133 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |
| Tocilizumab-bavi | Tofidence | C9399 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |
| Tocilizumab-bavi | Tofidence | J9999 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |
| Topotecan - inj | Hycamtin | J9351 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Topotecan - oral | Hycamtin | J8705 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Toripalimab-tpzi | Loqtorzi | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Toripalimab-tpzi | Loqtorzi | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trabectedin | Yondelis | J9352 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trastuzumab | Herceptin | J9355 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trastuzumab and hyaluronidase-oysk | Herceptin Hylecta | J9356 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trastuzumab-anns | Kanjinti | Q5117 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-dkst | Ogivri | Q5114 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-dttb | Ontruzant | Q5112 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-pkrb | Herzuma | Q5113 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | AultCare Commerical | Drug Comments |
|----------------------|-----------------------|---------|--------------------------|----------------------|--------------------------|---------------------|---------------|
| Trastuzumab-qyyp | Trazimera | Q5116 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Tremelimumab-actl | Imjudo | J9347 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trilaciclib | Cosela | J1448 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Triptorelin Pamoate | Trelstar | J3315 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Valrubicin | Valstar | J9357 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vinblastine Sulfate | Velban | J9360 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vincristine Sulfate | Oncovin, Vincasar PFS | J9370 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vinorelbine Tartrate | Navelbine | J9390 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ziv-Aflibercept | Zaltrap | J9400 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Zoledronic Acid | Zoledronic Acid | J3489 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |